AMIVANTAMAB

Information current as at: 1 June 2026

PBAC meeting date: July 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Rybrevant SC®
Form and strength:: Solution for subcutaneous injection 1600 mg in 10 mL

Solution for subcutaneous injection 2240 mg in 14 mL

Solution for subcutaneous injection 2400 mg in 15 mL

Solution for subcutaneous injection 3520 mg in 22 mL
Submission sponsor:: JANSSEN-CILAG PTY LTD
Condition/indication: (therapeutic use): Non-small cell lung cancer (NSCLC)
Listing requested:: To request listing of a new subcutaneous form of amivantamab for the first-line treatment (in combination with platinum-based chemotherapy) and second-line treatment (as monotherapy) of adult patients with locally advanced or metastatic NSCLC with an epidermal growth factor receptor gene mutation.
Funding program:: PBS General Schedule PBS Section 100 (Efficient Funding of Chemotherapy)
Request authority level:: Authority Required (Telephone/Online)
PBAC Submission type:: New PBS listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: July 2026 PBAC meeting
Opportunity for consumer comment:: Open 25/03/2026 and close 20/05/2026 (see PBS Website)
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

1208

Page last updated

31 May 2026

v.9.19